- Home
- AGL vs VIVS Comparison
AGL vs VIVS Comparison
Compare AGL & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGL | VIVS |
|---|---|---|
| Price | $10.74 | $1.69 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $66.48 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 60.3K |
| Earning Date | 05-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | $5.02 | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.25 |
| 52 Week High | $9.80 | $5.30 |
Technical Indicators
Market Signals| Indicator | AGL | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 96.91 | 43.93 |
| Support Level | $0.69 | N/A |
| Resistance Level | N/A | $2.21 |
| Average True Range (ATR) | 0.39 | 0.14 |
| MACD | 1.12 | -0.01 |
| Stochastic Oscillator | 97.82 | 60.32 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.